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Summary In Fabry disease a deﬁciency of -galactosidase A (-gal A) activity leads to accumu-
lation of globotriaosylceramide (Gb3) in various tissues including the heart. A speciﬁc cardiac
variant of Fabry disease has also been described. Previously we have demonstrated the fea-
sibility of gene therapy for Fabry disease. Here, to provide efﬁcient transfer and increased
speciﬁcity of transgene expression, we synthesized lentiviral vectors (LVs) with myocardial-
speciﬁc promoters including: -myosin heavy chain (-MHC), myosin light chain (MLC2v), and
cardiac troponin T (cTnT). Initially, neonatal Balb/c mice were injected with such LV constructs
engineering expression of luciferase. One month post-injection, we found speciﬁc expression
of luciferase in hearts of recipient animals when compared with transgene expression driven by
the standard EF1- promoter. To examine the feasibility of long-term therapy speciﬁcally tar-
geting the heart, recombinant LV/-gal A therapeutic vectors with analogous cardiac promoters
were generated and injected into numerous neonatal Fabry mice. No immune response against
the corrective -gal A hydrolase was observed in the treated mice. Serum -gal A activity of
10-week-old Fabry mice was increased in LV/-gal A-injected animals compared to controls.
In 28-week-old Fabry mice we observed signiﬁcantly decreased Gb3 accumulation. Neonatal
injections with LVs harboring cardiac-speciﬁc promoters may thus be an effective long-term
treatment strategy for heart manifestations and cardiac variant Fabry disease. These results
er pcan be also extended to oth
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ntroductionabry disease is an X-linked lysosomal storage disorder
LSD) caused by mutations of the GLA gene that result
n a deﬁciency of -galactosidase A (-gal A) activity [1].
eﬁciency of -gal A leads to the accumulation of neutral
Published by Elsevier Ltd. All rights reserved.
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lycosphingolipids, including globotriaosylceramide (Gb3)
nd galactosylceramide. These glycosphingolipids accumu-
ate in many tissues and cell types including the nervous
ystem, skin, kidney, and heart. Although lysosomal accumu-
ation of Gb3 begins during the prenatal period, symptoms
sually develop in early childhood [2]. These severe clinical
ymptoms include burning pain, acroparesthesia, gastroin-
estinal disturbance, cutaneous angiokeratomata, corneal
eposits, renal dysfunction, stroke, cardiac arrhythmias,
nd left ventricular hypertrophy [3]. Heart disease has been
dentiﬁed as a major complication of Fabry disease. It con-
ributes substantially to morbidity and results in premature
eath from heart failure, arrhythmia, and stroke [4,5].
ardiac variant Fabry disease has also been described [6]
herein manifestations are organ speciﬁc.
As little as 5—10% of residual -gal A enzyme activ-
ty has been shown to be sufﬁcient to prevent clinically
igniﬁcant Gb3 accumulation [3]. Accordingly, therapeutic
pproaches for Fabry disease aim to increase -gal A activ-
ty and thereby decrease Gb3 levels. To date, methods to
chieve this have included enzyme replacement therapy
ERT), molecular chaperone therapy, and gene therapy. The
iffusion and re-uptake of -gal A provides the rationale
or both ERT and gene therapy. Although ERT has been
hown to reduce Gb3 levels in cardiac tissue and vascular
ndothelial cells in some studies [7—9], long-term clinical
eneﬁt remains to be determined and most patients receiv-
ng ERT develop immunoglobulin (Ig) G antibodies against
he infused enzyme [10—12]. In the context of gene therapy,
abry disease is a good candidate for implementation of this
pproach as it is a well-characterized single gene disorder
nd such a therapeutic approach could provide a long-term
ure for the disorder [13].
Gb3 has been found to accumulate in cardiomyocytes,
alvular ﬁbroblasts, endothelial cells, conduction system
ells, and vascular smooth muscle cells [4] causing cellu-
ar dysfunction by triggering intracellular signaling pathways
eading to hypertrophy, apoptosis, necrosis, and ﬁbrosis.
hese dysfunctions then contribute to congestive heart
ailure, myocardial ischemia or infarction, left ventricular
ypertrophy, anginal chest pain, conduction defects, valvu-
ar insufﬁciency, and hypertension, that also manifest in
ate stages of Fabry disease. Management and prevention
f cardiac symptom complications in Fabry disease relies
n the use of conventional therapies for which there is evi-
ence of beneﬁt in other heart disorders. That said, not all
he symptoms or illness have been ameliorated after such
reatments.
In previous studies, we have been developing recombi-
ant human immunodeﬁciency virus (HIV)-1-based lentiviral
ector (LV)-mediated gene therapy for Fabry disease. In
hose studies, we primarily focused on directly overex-
ressing -gal A to provide local intracellular and systemic
orrection of disease [14,15]. We have also sought to correct
ardiac Fabry disease using direct intra-ventricular injec-
ion of a recombinant LV that engineers expression of -gal
[16]. Those studies all indicated that successful correc-ion of -gal A activity and reduction of Gb3 levels in heart
issue could be achieved. Here we sought to employ a less
nvasive procedure than direct cardiac injections into adult
nimals and yet to still generate long-term, organ-directed
ubstrate reduction.
3
h
i
G
aC.-J. Lee et al.
LVs are ideal gene delivery vehicles given their broad
ell tropism and gene delivery efﬁciency. The concerns of
sing viral vectors therapeutically for gene transfer depend
n the efﬁcacy of gene transfer and more importantly on
afety. The restriction of transgene expression to speciﬁc
arget cells is highly desirable for preventing unpredictable
ffects in other cell types. Due to the broad transduction
fﬁciency of LVs employing usual pseudotyping, targeting
nfection of such LVs to particular cell types has proven to
e challenging, however. Attempts have been directed to
ngineering the viral glycoprotein to recognize a speciﬁc cel-
ular target by insertion of ligands, peptides, or antibodies
17—19]. Another approach involves the use of glycopro-
eins from other viruses, such as measles and Ebola viruses
20,21]. Modiﬁcations to the surface glycoprotein, however,
ppear to disturb the production and natural fusion func-
ion of the glycoprotein and can result in lower viral titers
nd transduction efﬁciencies. The use of cell-type-speciﬁc
romoters, which avoids the expression of the therapeu-
ic transgene in non-target cells, can improve efﬁcacy and
afety of LV-mediated gene transfer, even in the setting of
ystemic vector administration.
As for other LSDs, early therapeutic correction of Fabry
isease may prove to be a more effective intervention
han delayed treatment. In addition, therapy that can
lso be effected within the context of immunological
olerance is optimal. Neonatal delivery is a strategy to
chieve tolerance to the transgene given that the recipi-
nt’s immune system is not yet fully developed. In fact,
e have provided evidence to demonstrate that neonatal
njection of LV to treat Fabry disease is feasible [14]. In
his present study, we developed LVs harboring myocardial-
peciﬁc promoters that engineer transgene expression in
he heart. We tested such promoter speciﬁcity in neona-
al LV-transduced animals. Our data demonstrated that this
elivery method can effectively correct the long-term stor-
ge of Gb3 in the hearts of Fabry mice and provides a
latform for adapting this approach for other progressive
ardiac pathologies.
aterials and methods
V vector construction
he HIV-1-based recombinant LV backbone pCCL was kindly
rovided by Dr. Luigi Naldini (San Raffaele Telethon Insti-
ute for Gene Therapy, Vita Salute San Raffaele University,
ilan, Italy) [22]. Brieﬂy, LVs were constructed using the
ontrol EF1- [14] and test myocardial-speciﬁc promoters
ncluding: -myosin heavy chain (-MHC) [23], myosin light
hain 2v (MLC2v) [24], and cardiac troponin T (cTnT) [25],
o drive ﬁreﬂy luciferase (F-Luc) or -gal A expression. The
romoter region of -MHC (−1198 to +1), MLC2v (−250 to
13), and cTnT (−300 to +1) were used in this study. The
rimers 5′-AGGCGCGCCGCCACCATGCAACTTCGAAACCC-3′
nd 5′-CGGGATCCTCACAGAAGATCCTTAAGTGACATCTGC-
′ were used to subclone the human codon-optimized
uman -gal A cDNA sequence (manuscript in preparation)
nto the LV backbone. The primers 5′-CGGATATCATG-
CGCGCCGCCACCATGGAAGACGCCAAAAACATAAAGAAAG-3′
nd 5′-CGGGATCCTTACACGGCGATCTTTCCGCC-3′ were used
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to amplify F-Luc from our previous construct [14] and
subclone it into the pCCL backbone.
LV production and titration
VSV-G-pseudotyped LVs were generated by transient
transfections of 293T cells with three plasmids (LV
plasmid construct, packaging plasmid pCMV8.91, and
the VSV-G envelope-coding plasmid pMD.G) using the
polyethyleneimine-transfection procedure as described pre-
viously [26]. The concentrated virus was suspended in
serum-free RPMI-1640 medium and stored at −80 ◦C until
use. Viral titers were determined using an HIV-1 p24 enzyme-
linked immunoassay (ELISA) kit (PerkinElmer Canada Inc.,
Vaudreuil-Dorian, QC, Canada).
Mice and temporal vein injections of recombinant
LVs
The animal experimentation procedures were performed
under protocols approved by the University Health Network
(UHN) Animal Care Committee. C57BL/6 and BALB/c mice
were purchased from The Jackson Laboratory, Maine, USA.
All the mice including -gal A-deﬁcient Fabry mice [14]
were maintained in the animal facility at the UHN. The
viral administration procedure was performed in 1-day-old
mice by injection of a maximum of a 100l volume of virus
(normalized to 300 ng p24 titer for each construct) into the
superﬁcial temporal vein of each recipient using a 30-gauge
needle [26].
Ex vivo organ bioluminescent imaging
Bioluminescent imaging was performed with an IVIS Imag-
ing System (Xenogen, Alameda, CA, USA) comprising a
charge-coupled device camera mounted in a light-tight
camera box in the Advanced Optical Microscopy Facility
at the UHN. Images and measurements of bioluminescent
signals were acquired and analyzed using Living Image
software (Xenogen). Brieﬂy, mice were anesthetized and
administered D-luciferin (Molecular Imaging Products, Ann
Arbor, MI, USA) at 100mg/kg dose in phosphate buffered
saline (PBS) by intraperitoneal (i.p.) injection. Two min-
utes after receiving the D-luciferin, mice were killed and
organs were collected for image acquisition (5min exposure
times).
Titration of anti--gal A antibody
Microtiter-plate-based ELISAs were used to detect anti-
human -gal A antibody in 7-week-old mice. Brieﬂy, 50 ng
of recombinant human -gal A (kindly provided by Dr.
Roscoe Brady, NIH, Bethesda, USA) was coated in Immu-
lon2 HB Flat Bottom Microtiter Plates (ThermoLabsystems,
#3455, Waltham, USA). The nonspeciﬁc antibody-binding
sites were blocked with 5% bovine serum albumin and
0.1% Tween-20 in PBS. Plasma samples were added to
the plate and then reacted with horseradish peroxidase-
conjugated anti-mouse IgG antibody (Biorad, 172-1011,
Hercules, USA). Finally, 3,3′,5,5′-tetramethylbenzidine liq-
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id substrate (Sigma, T0440, Oakville, Canada) was used to
evelop the plates.
-Gal A activity assay and high pressure liquid
hromatography quantitation of Gb3 levels
-Gal A activity was measured by a microtiter-plate-based
uorometric assay as described previously [14]. Plasma or
eart samples were added to a microtiter-plate reader
Dynex, Chantilly, VA, USA), and the 4-methylumbelliferone
roduct was determined quantitatively by comparison with
nown standards (Sigma). Plasma samples were collected,
entrifuged, and assayed directly. Frozen mouse heart tis-
ues were homogenized with a tissue homogenizer twice
or 10 s each in the assay buffer (28mM citric acid/44mM
isodium phosphate, and 5mg/ml sodium taurocholate, pH
.4) before sonication. High pressure liquid chromatography
HPLC) analyses of Gb3 levels in mouse heart extracts were
erformed as previously described [14]. The assay read-
uts were normalized against total protein concentrations
s determined by the DC Protein Assay Kit (Biorad).
ata and statistical analysis
ll data are presented as mean± standard deviation (SD).
tatistical analyses were performed using Microsoft Excel
oftware. Student’s t-tests were used for comparisons
etween LV-treated and non-treated Fabry mouse groups.
esults
xpression distribution patterns of LVs harboring
yocardial-speciﬁc promoters following temporal
ein injection into neonatal mice
s it is difﬁcult to target speciﬁc LV infection to one par-
icular cell population, restriction of gene expression by
issue-speciﬁc promoters is important. Myocardial-speciﬁc
romoters have been used to drive gene expression in
everal viral vectors, including LV, adenovirus, and adeno-
ssociated virus [24,27,28]. Nevertheless, speciﬁcity and
ransgene expression efﬁciency in vivo are still not fully
haracterized in the ﬁeld. To study the speciﬁcity and
xpression efﬁciency of cardiac promoters in our LV sys-
em in vivo, we constructed and systematically compared
hree different promoters (-MHC, MLC2v, and cTnT) in
he LV backbone (LV/F-Luc) driving ﬁreﬂy luciferase expres-
ion (Fig. 1). One-day-old Balb/c mice were injected
ith LV/F-Luc (-MHC, MLC2v, or cTnT) in the tempo-
al vein to generate systemic viral distribution. Control
ice received LV carrying the housekeeping EF1- promoter
riving the expression of F-Luc. Transgene expression in
-week-old mice was detected by bioluminescence imag-
ng. We found that luminescent signals generated by
uciferase activity were detectable in all four groups of
accinated mice (Fig. 2A). Expression mediated by the
ontrol EF1- promoter was ubiquitous; this conﬁrmed
hat this delivery schema allows systemic vector distribu-
ion as we have seen before [14]. Concerning the -MHC
roup, this promoter was primarily active in the heart
118 C.-J. Lee et al.
Figure 1 A schema of LV/F-Luc and LV/-gal A constructs. LV, lentiviral vector; LTR, long-terminal repeat; RRE, rev response
e

i
F
i
r
o
s
plement; cPPT, central polypurine tract; -MHC, MLC2v, or cTnT: m
-galactosidase A; F-Luc, ﬁreﬂy luciferase; WPRE, woodchuck hep
nactivating LTR.
igure 2 Ex vivo bioluminescent images of luciferase expression in
stration. Four weeks post-injection of LV/ﬁreﬂy luciferase (F-Luc),
emoved. Imaging was performed using a charge-coupled device ca
rgans of representative mice from each group. (B) The bioluminesce
oftware. Results are from 2 to 3 independent experiments. EF1-
romoters; PBS, phosphate-buffered saline.yocardial promoters; EF1-, housekeeping promoter; -gal A,
atitis virus post-transcriptional regulatory element; SIN, self-
mouse organs following neonatal lentiviral vector (LV) admin-
mice were administered D-luciferin i.p. and the organs were
mera. (A) Bioluminescent images of luciferase activity in the
nt signal from each organ was quantiﬁed using the Living Image
, housekeeping promoter; -MHC, MLC2v, or cTnT: myocardial
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Figure 3 Plasma -galactosidase A (-gal A) activity in lentiviral vector (LV)-injected Fabry mice. Plasma from numerous naïve
trol m
ﬂuoro
ups.
n
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iFabry mice, LV/-gal A-injected Fabry mice, and wild-type con
-Gal A activity was determined by a microtiter-plate-based
*p < 0.05 vs. Fabry mouse groups, **p < 0.01 vs. Fabry mouse gro
and not in other organs. Major luciferase activity in the
MLC2v group was in the heart, although lower levels in
the spleen and liver were also detected. The cTnT pro-
moter exhibited stronger activity; however it also showed
less tissue speciﬁcity in the injected mice. The intensity
of bioluminescent signal from each organ as calculated
by Living Image software indicated that the -MHC pro-
moter had the highest heart speciﬁcity in our LV delivery
model when compared to the MLC2v or cTnT promoters
(Fig. 2B).
Plasma -gal A activity in LV/-gal A-injected Fabry
mice
As demonstrated above, the LV harboring myocardial
promoters could efﬁciently and speciﬁcally deliver the
transgene payload to the targeted cardiac tissues. To inves-
tigate the ability of such LVs to lead to functional correction
in heart disease, we used the Fabry mouse model to con-
duct therapeutic studies. For these studies, we generated
a
t
l
t
oice were collected at 7, 10, 20, and 24 weeks post-injection.
metric assay and normalized to total protein concentration.
-MHC, MLC2v, or cTnT: myocardial promoters.
ovel -gal A-cDNA LVs harboring heart speciﬁc promoters
Fig. 1). Ultimately we sought to evaluate the functional
ffectiveness of these constructs on the prevention of Gb3
ccumulation in Fabry mice. As an initial therapeutic read-
ut, however, plasmas from naïve Fabry mice, LV/-gal
-injected Fabry mice, and wild-type (WT) control mice
ere collected at 7, 10, 20, and 24 weeks post-LV injection
nto 1-day-old Fabry mice. -Gal A activity in the plasma
as then determined by a microtiter-plate-based ﬂuoro-
etric assay (Fig. 3). In general, systemic enzyme activity
evels are expected to be low given the reduced activ-
ty of these tissue-speciﬁc promoters and the fairly rapid
learance of -gal A from the plasma. In the -MHC group,
hich demonstrated more speciﬁc transgene expression in
he heart (Fig. 2), the -gal A activity had a signiﬁcant
ncrease in the plasma compared to the other groups only
t 10-weeks post-injection. These results suggested that
he highly speciﬁc -MHC promoter may produce some low
evel of -gal A for systemic secretion. In the MLC2v group,
here were no signiﬁcant changes in plasma -gal A activity
bserved at the indicated time points. In the cTnT group,
120 C.-J. Lee et al.
Figure 4 Absence of anti--galactosidase A (-gal A) antibody
in the plasma of lentiviral vector (LV)-injected mice. The anti-
body levels against human -gal A in the plasma of naïve Fabry
mice, LV/-gal A-injected Fabry mice, and wild-type control
mice were determined at 7 weeks post-injection. Serum from
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Figure 5 -Galactosidase A (-gal A) activity and globo-
triaosylceramide (Gb3) levels in the hearts of lentiviral vector
(LV)-injected mice. Hearts from numerous LV/-gal A-injected
Fabry mice, naïve Fabry mice, and wild-type control mice were
harvested at death when the mice reached 28 weeks of age.
-Gal A activity assays (A) and Gb3 accumulation (B) were ana-
lyzed by using a microtiter-plate-based ﬂuorometric assay and
h
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tice immunized with recombinant -gal A protein was used as
positive control for the antibody reaction. -MHC, MLC2v, or
TnT: myocardial promoters.
hich demonstrated broader luciferase expression in the
eart, lung, liver, and spleen, signiﬁcant changes in plasma
-gal A activity were detected at 10, 20, and also 24 weeks
ost-injection.
etermination of anti--gal A antibody levels in
V/-gal A-injected mice
n Fabry mice, the corrective -gal A protein itself can
ct as an immunogen given that these mice are GLA−/−.
o determine whether the neonatally injected mice pro-
uce antibodies against -gal A post-LV administration, we
ested for anti--gal A antibody levels by ELISA in naïve
abry mice, LV/-gal A-injected Fabry mice, and WT con-
rol mice (Fig. 4). The results indicated that no treatment
roup produced anti--gal A antibodies above background
evels. As no immune response was detected against the
ransgene, this re-enforces that such neonatal therapy can
olerate individuals to the ‘‘foreign’’ therapeutic corrective
roduct.
-Gal A activity and Gb3 accumulation in hearts of
V/-gal A-injected Fabry mice
ustained production of low levels of -gal A activity in the
eart may sufﬁce to decrease substrate load in that impor-
ant organ for the management of Fabry disease. To further
valuate the therapeutic efﬁcacy, hearts from LV/-gal A-
njected Fabry mice, naïve Fabry mice, and WT control mice
ere harvested for analysis of -gal A activity and quanti-
ation of Gb3 accumulation. Compared to the control naïve
abry mice, the -gal A activity in the cTnT LV-transduced
roup was signiﬁcantly increased; however, this change was
ot found in -MHC and MLC2v groups (Fig. 5A). Although
nly small changes in -gal A activity were detected in the
t
s
t
w
Gigh pressure liquid chromatography quantitation, respectively.
p < 0.05 vs. Fabry groups; **p < 0.01 vs. Fabry groups. -MHC,
LC2v, or cTnT: myocardial promoters.
eart at this single time point, Gb3 accumulation may more
irectly relate to the sustained therapeutic efﬁciency of
his vaccination strategy over time. Gb3 accumulation in
he heart was analyzed by HPLC in 28-week-old mice post
ortem. Gb3 accumulation was signiﬁcantly reduced among
ll the -MHC, MLC2v, and cTnT groups compared to naïve
abry mice (Fig. 5B). These results indicate that the gene
herapy was targeted to the heart and the transgene of
nterest was expressed at sufﬁcient levels for therapeutic
urposes.
iscussion
n this study, we compared the speciﬁcity and expression of
hree myocardial promoters in the context of LV transduc-
ion in vivo. We found that the -MHC promoter exhibited
igniﬁcantly higher speciﬁcity in LV-transduced mice than
he MLC2v and cTnT promoters. In the Fabry mouse model,
e found that LVs carrying myocardial promoters and the
LA cDNA efﬁciently reduced Gb3 accumulation in the heart
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despite the lack of appreciable changes in -gal A activity.
Antibody induction was also not observed. Such low levels of
continued enzyme activity delivered early into the speciﬁc
organ of interest may be more effective and cost manage-
able to correct such cardiac manifestations of Fabry disease
than large boluses of enzyme injected on a bi-weekly basis
as occurs in ERT for this disorder.
The myocardial promoters (-MHC, MLC2v, and cTnT)
that we used in this study have been reported to exhibit
myocardial-speciﬁc expression [23—25]. The -MHC pro-
moter from −5446 bp to −4 bp relative to ATG (includes
non-coding exons 1, 2, and UTR of exon 3) has been uti-
lized in other studies due to its cardiac-speciﬁc expression
[23,29]. In the context of LVs, however, the larger size of this
canonical cardiac promoter impacts feasibility issues con-
cerning LV construction and production. Here, we minimized
the -MHC promoter to 1.2 kb (−1198 to +1), which included
the Trans, MEF-1, MEF-2, MCAT, and CArG elements that
have been shown to be important for myocardial-speciﬁc
expression [23]. Indeed, these modiﬁcations did not affect
the cardiac speciﬁcity of the -MHC promoter in our study
(Fig. 2). Furthermore, the MLC2v promoter (−250 to +13)
that we used in this study has been proven to engineer
myocardial-speciﬁc expression in the ventricle of the heart
in transgenic mice [30]. In this present study, we found
that the MLC2v promoter also drove gene expression in the
spleen; this was not reported in the study by Lee et al. [30].
This was possibly due to the different gene delivery method
utilized in our study. Whereas our delivery method was deliv-
ered systemically in the mouse very early after birth by LV
administration, Lee et al. utilized DNA micro-injection into
fertilized oocytes. It is possible that the MLC2v promoter
may also generate low-level expression in splenocytes as
indicated by the myosin light chain 1 atrial isoform (MLC1A)
promoter, which has been reported to drive gene expres-
sion in pre-B cells [31]. The −303 bp segment of the cTnT
promoter, which contains TCTG(G/C) direct repeat, GATA
consensus sequence, MEF2-like sequence, and an A/T-rich
site, has myocardial-speciﬁc expression in vitro [25]. In fact,
the −249 bp proximal promoter of cTnT is sufﬁcient to drive
cardiac-speciﬁc expression of a transgene in transgenic mice
[32]. Interestingly, this cTnT fragment is not sufﬁcient to
provide heart speciﬁc expression in our LV-transduced mice.
This discrepancy is most probably attributed to the strength
of the cTnT promoter in the context of the LV backbone.
A major problem of most tissue-speciﬁc promoters is
their relatively weak transcriptional activity. This limits
their extensive use in gene therapy applications. To pos-
sibly address this problem, the human cytomegalovirus
(CMV) immediate-early enhancer has been used to enhance
transgene transcription in both non-viral plasmid vectors
and viral vectors. For example, the CMV enhancer has
been combined with tissue-speciﬁc promoters such as the
platelet-derived growth factor -chain (PDGF-) promoter,
human atrial natriuretic factor (hANF) promoter, human
ventricular myosin light chain (hMLC2v) promoter, and the
human surfactant protein C (SP-C) promoter. The combi-
nation of this enhancer element and those tissue-speciﬁc
promoters has been shown to confer an increase in gene
expression without compromising tissue speciﬁcity [28,33].
Our future constructs will determine the validity of this
addition in our therapeutic schema. Indeed, we have121
bserved an enhancement of myocardial-speciﬁc promoter
xpression by including the CMV enhancer in bi-directional
V constructions (unpublished data). Furthermore, strate-
ies to increase LV transduction efﬁciency during neonatal
ystemic vector administration have been devised and uti-
ized with some success. For example, vascular endothelial
rowth factor-A (VEGF-A) was a vasodilator and originally
iscovered as a vascular permeability factor. It induced
ermeability with extraordinarily rapid kinetics and 50,000
imes more effectiveness than histamine [34,35]. In our pre-
ious study, Sato et al. showed that pretreatment of VEGF
n neonatal mice enhanced the efﬁciency of LV delivery to
he heart as well as to other organs [26]. Such strategies may
lso be adaptable to the present therapeutic considerations.
In summary, our results support the use of LV harbor-
ng cardiac-speciﬁc promoters to provide long-term heart
issue-speciﬁc expression of therapeutic transgenes. These
roof-of-principle results can be also extended to other con-
itions involving progressive pathologies of the heart.
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